Mathew Cherian
Ohio State University
63 Papers
74 Citations
Mathew Cherian is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 10, co-authored 37 publications. Previous affiliations of Mathew Cherian include University of North Dakota & AbbVie.
Chat about Author
Papers
Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Brooke Benner,Logan Good,Dionisia Quiroga,Thomas E Schultz,Mahmoud Kassem,William E. Carson,Mathew Cherian,Sagar Sardesai,Robert Wesolowski +8 more
TL;DR: The biology ofTGCT is discussed and the pre-clinical and clinical development of pexidartinib which ultimately led to the FDA approval of this agent for the treatment of TGCT is reviewed, as well as ongoing clinical studies utilizing peXidart inib in the setting of cancer.
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
TL;DR: Gene signatures predictive of Hh pathway activation could enrich for patients likely to respond to these agents, and GLI1 inhibitors like GANT58 and GANT61 are in preclinical drug development and might be an effective mechanism to overcome drug resistance in breast cancer.
110
Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor.
Rahul Mal,Alexa Magner,Joel David,Jharna Datta,Meghna Vallabhaneni,Mahmoud Kassem,Jasmine Manouchehri,Natalie Willingham,Daniel G. Stover,Jeffery Vandeusen,Sagar Sardesai,Nicole Williams,Robert Wesolowski,Maryam B. Lustberg,Ramesh K. Ganju,Bhuvaneswari Ramaswamy,Mathew Cherian +16 more
TL;DR: ERβ is a nuclear receptor with broad-spectrum tumor suppressor activity, which could serve as a potential treatment target in a variety of human cancers including breast cancer.
•Journal Article
Biochemical and clinical profile after organophosphorus poisoning--a placebo-controlled trial using pralidoxime.
TL;DR: Treatment with P2AM does not make any difference in butyryl cholinesterase reactivation or complications of moderate and severe OP poisoning, and it has not been used for OP poisoning in the medical ICU with good patient outcomes.
48
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Otto Metzger Filho,Daniel G. Stover,Sarah Asad,Peter Ansell,Mark A. Watson,Sibylle Loibl,Charles E. Geyer,Charles E. Geyer,Junu Bae,Katharine Collier,Mathew Cherian,Mathew Cherian,Joyce O'Shaughnessy,Michael Untch,Hope S. Rugo,J Huober,J Huober,Mehra Golshan,Mehra Golshan,William M. Sikov,Gunter von Minckwitz,Priya Rastogi,David Maag,Norman Wolmark,Carsten Denkert,W. Fraser Symmans +25 more
TL;DR: In this article, the authors defined the association of molecular subtype, tumor proliferation, and immunophenotype with benefit of carboplatin added to NAC for patients with stages II to III TNBC.
46